Advance Directive

 

An advance directive is a personal statement of how medical care choices should be made and who should make them in the event you are unable to communicate for any reason. A medical power of attorney appoints a specific person (called a health care agent or proxy) to make medical treatment decisions for you, in accordance with your wishes, in the event you are incapacitated. A living will states what kinds of care you want and do not want, and under which circumstances.

Advance directives should be documented and comply with the laws or guidelines in a person's state of residence. Generally, two people witness your signature of the documents. These should be people who are neither designated health care agents nor beneficiaries of the person making the directive. The provisions of your advance directive, such as when to continue or abandon life-support measures, should also be discussed with your health care professional, family members, and your designated health care agent, as well as any other potential decision makers.

It is important to remember that advance directives only come into play if you are incapacitated and cannot make choices and decisions for yourself. As long as you are of sound mind and able to communicate your wishes, you have the right to make any medical choices you desire. You can change your mind at any time, and in fact, you need not comply with your own previously stated advance directives if your wishes or circumstances change. Advance directives are only for others to use and follow in case you can't communicate your wishes yourself.

Latest Cancer News
ACOG Updates Cervical Cancer Screening Guidelines

November 20, 2009 — The American College of Obstetricians and Gynecologists (ACOG) has revised its cervical cancer screening recommendations: the organization now recommends that women begin screening at the age of 21 and receive screening at less frequent intervals. These recommendations will be published in the December 2009 issue of Obstetrics and Gynecology.

New Velcade®-melphalan Transplant Regimen for Multiple Myeloma

November 20, 2009 — Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.

Folic Acid May Be Beneficial in Patients with Recurrent Colorectal Adenoma Who Are Folate Deficient

November 20, 2009 — Researchers affiliated with the Health Professional Follow-Up Study and the Nurses’ Health Study have reported that folic acid supplementation in patients with recurrent colorectal adenoma was not protective or harmful in most patients. However, patients who were folate deficient had a significant 39% decrease in adenoma recurrence. The details of this study appeared in an early online publication on October 28, 2009 in the American Journal of Clinical Nutrition.

Select news items provided by Reuters Health